Skip To Main Content
Mike Liu on Muck Rack

Mike Liu

As seen in: LinkedIn, Amazon Web Services, Medium, Nature, A Health Podyssey, EIN News, EIN Presswire, Hoover Institution, Virginia Tech Collegiate Times, RESPECT. and

Get in touch with Mike

Contact Mike, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

|
By Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert F. Kushner, Andres Acosta, Thomas C. Blevins, Timothy Smith, Lisa Connery, Yao Li, Mike Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04476-6, published online 5 June 2026. In the version of the article initially published, in Fig. 3b, the Aleniglipron 120 mg column initially listed LS mean change as “–12.1” and has been updated to read “–12.7,” while in Fig. 4, the data was missing from the bottom-right panel, and all arrows were missing from the “Vomiting” panels. Figures 3 and 4 have now been corrected in the HTML and PDF versions of the article.
Open in Who Shared Issue with article?

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

|
By Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert F. Kushner, Andres Acosta, Thomas C. Blevins, Timothy Smith, Lisa Connery, Yao Li, Mike Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll
| Nature Verified
Abstract Aleniglipron is an oral, small-molecule glucagon-like peptide-1 receptor agonist (GLP1-RA) in development for obesity treatment. The ACCESS phase 2b placebo-controlled, double-blind study randomized 230 adults (mean BMI 39.5 kg m−2, 54% female) with obesity or overweight to examine the effects of once-daily aleniglipron escalated every 4 weeks to 45, 90 or 120 mg.
Open in Who Shared Issue with article?

Introducing a powerful new chapter for Windows PCs, accelerated by NVIDIA RTX Spark

|
By Kiryl Bahdanau, Mike Liu, Robert Blokker
| LinkedIn
Our goal is to deliver unmetered intelligence to every home and every desk with Windows. NVIDIA RTX Spark marks a real breakthrough toward that vision. Looking forward to sharing more with Jensen, who will be joining us live from Taiwan, at Build this week! https://lnkd.in/gWNdTJ6v
Open in Who Shared Issue with article?
See all 133 articles